Expression of apoptosis regulators in cutaneous malignant melanoma

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1865-1871

  Tang, Liren ^a   Tron, Victor A ^a,c   Reed, John C ^b   Mah, Karen J ^a   Krajewska, Maryla ^b   Li, Gang ^a   Zhou, Xiwu ^a   Ho, Vincent C ^a   Trotter, Martin J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BURNHAM INSTITUTE   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS;

EID: 0031850559     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Koh, H. K. Cutaneous melanoma. N. Engl. J. Med., 325: 171-182, 1991.
2. Roses, D. F., Karp, N. S., Oratz, R., Dubin, N., Harris, M. N., Speyer, J., Boyd, A., Golomb, F. M., Ransohoff, J., Dugan, M., Valentine, F. T., Cooper, J., and Bystryn, J. C. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg. Gynecol. Obstet., 172: 262-268, 1991.
3. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
4. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
5. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
6. Staunton, M. J., and Gaffney, E. F. Tumor type is a determinant of susceptibility to apoptosis. Am. J. Clin. Pathol., 103: 300-307, 1995.
7. Mooney, E. E., Ruis-Peris, J. M., Neill, A., and Sweeney, E. C. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J. Clin. Pathol., 48: 242-244, 1995.
8. Harmon, B. V., Takano, Y. S., Winterford, C. M., and Gobe, G. C. The role of apoptosis in the response of cells and tumours to mild hyperthermia. Int. J. Radiat. Biol., 59: 489-501, 1991.
9. Williams, G. T., and Smith, C. A. Molecular regulation of apoptosis: genetic controls on cell death. Cell, 74: 777-779, 1993.
10. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
11. Stewart, B. W. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J. Natl. Cancer Inst., 86: 1286-1296, 1994.
12. Wyllie, A. H. The genetic regulation of apoptosis. Curr. Opin. Genet. Dev., 5: 97-104, 1995.
13. Reed, J. C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. Am., 9: 451-474, 1995.
14. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J-T., Tu, S-M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
15. Matsushima, H., Hosaka, Y., Suzuki, M., Mizutani, T., Ishizuka, H., and Kawabe, K. Bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int. J. Urol., 3: 113-117, 1996.
16. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
17. Joensuu, H., Pylkkänen, L., and Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
18. Gasparini, G., Barbareschi, M., Doglioni, C., Dalla Palma, P., Mauri, F. A., Boracchi, P., Bevilacqua, P., Caffo, O., Morelli, L., Verderio P., Pezzella, F., and Harris, A. L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1: 189-198, 1995.
19. Lipponen, P., Pietiläinen, T., Kosma, V-M., Aaltomaa, S., Eskelinen, M., and Syrjänen, K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol., 177: 49-55, 1995.
20. Hurlimann, J., Larrinaga, B., and Vala, D. L. Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch., 426: 163-168, 1995.
21. Diebold, J., Baretton, G., Felchner, M., Meier, W., Dopfer, K., Schmidt, M., and Löhrs, U. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am. J. Clin. Pathol., 105: 341-349, 1996.
22. Herod, J. J. O., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L. S., and Kerr, D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res., 56: 2178-2184, 1996.
23. Öfner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Tötsch, M., Böcker, W., Jasani, B., and Schmid, K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer, 72: 981-985, 1995.
24. Fontanini, G., Vignati, S., Bignini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F., and Bevilacqua, G. Bcl-2 protein: a prognostic factor inversely correlated to in non-small-cell lung cancer. Br. J. Cancer, 71: 1003-1007, 1995.
25. Viale, G., Roncalli, M., Grimelius, L., Graziani, D., Wilander, E., Johansson, H., Bergholm, U., and Coggi, G. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum. Pathol., 26: 945-950, 1995.
26. van den Oord, J. J., Vandeghinste, N., De Ley, M., and De Wolf-Peeters, C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am. J. Pathol., 145: 294-300, 1994.
27. Saenz-Santamarfa, M. C., Reed, J. C., McNutt, N. C., and Shea, C. R. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J. Cutan. Pathol., 21: 393-397, 1994.
28. Tron, V. A., Krajewski, S., Klein-Parker, H., Li, G., Ho, V. C., and Reed, J. C. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol., 146: 643-650, 1995.
29. Ramsay, J. A., From, L., and Kahn, H. J. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod. Pathol., 8: 150-154, 1995.
30. Mooy, C. M., Luyten, G. P. M., de Jong, P. T. V. M., Luider, T. M., Stijnen, T., van de Ham, F., van Vroonhoven, C. C. J., and Bosman, F. T. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am. J. Pathol., 147: 1097-1104, 1995.
31. Sato, T., Hanada, M., Bodrug, S., Irie, S. Iwama, N., Boise, L. H., Thompson, C. B., Golemis, E., Fong, L., Wang, H-G., and Reed, J. C. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238-9242, 1994.
32. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
33. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., and Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA, 90: 3516-3520, 1993.
34. Reynolds, J. E., Yang, T, Qian, L, Jenkinson, J. D. Zhou, P., Eastman, A., and Craig, R. W. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res., 54: 6348-6352, 1994.
35. Boise, L. H., González-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., and Thompson, C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
36. Gradilone, A., Greco, C., Gazzaniga, P., Vercillo, R., Napolitano, M., Gandini, O., Mattei, F., Frati, L., and Aglian, A. M. BAX gene expression in melanoma metastases. J. Invest. Dermatol., 106: 382, 1996.
37. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H-G., Shinji, S., Fong, L., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res., 54: 5501-5507, 1994.
38. Krajewski, S., Bodrug, S., Krajewska, M., Shabaik, A., Gascoyne, R., Berean, K., and Reed, J. C. Immunohistochemical analysis of Mcl-1 protein in human tissues. Am. J. Pathol., 146: 1309-1319, 1995.
39. Krajewski, S., Krajewska, M., Shabaik, A, Miyashita, T., Wang, H. G., and Reed, J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol., 145: 1323-1336, 1994.
40. Thomas, A., El Rouby, S., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M., and Newcomb, E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12: 1055-1062, 1996.
41. Fang, W., Rivard, J. J., Mueller, D. L., and Behrens, T. W. Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes. J. Immunol., 153: 4388-4398, 1994.
42. Kitada, S., Krajewski, S., Miyashita, T., Krajewska, M., and Reed, J. C. Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene, 12: 187-192, 1996.
43. Zhan, O., Fan, S., Bae, I., Guillouf, C., Liebermann, D. A., Connor, P. M., and Fornace, A. J., Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743-3751, 1994.
44. Kajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V-M., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
45. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D., and Dörken, B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer, 60: 854-859, 1995.
46. Branet, F., Brousset, P., Krajewski, S., Schlaifer, D., Selves, J., Reed, J. C., and Caron, P. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J. Clin. Endocrinol. Metab., 81: 2726-2730, 1996.
47. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
48. Krajewska, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R., and Reed, J. C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res., 56: 2422-2427, 1996.
49. Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., and Perucho, M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (Washington DC), 275: 967-969, 1997.
50. Knudson, C. M., Tung, K. S. K., Tourtellotte, W. G., Brown, G. A. J., and Korsmeyer, S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science (Washington DC), 270: 96-99, 1995.
51. Middleton, G., Nuñez, G., and Davies, A. M. Bax promotes neuronal survival and antagonises the survival effects of neurotrophic factors. Development (Camb.), 122: 695-701, 1996.
52. Weiss, J., Schwechheimer, K., Cavenee, W. K., Herlyn, M., and Arden, K. C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer, 54: 693-699, 1993.
53. Li, G., Ho, V. C., Trotter, M. J., Horsman, D. E., and Tron, V. A. p53 mutation in metastatic melanomas and primary melanomas from sun-exposed and sun-protected sites. J. Eur. Acad. Dermatol. Venereol., 4: 48-53, 1995.
54. Li, G., Tang, L., Zhou, X., Tron, V. A., and Ho, V. Chemotherapy-induced apoptosis in melanoma cells is p53-dependent, in press, 1998.
55. Gottschalk, A. R., Boise, L. H., Thompson, C. B., and Quintáns, J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl. Acad. Sci. USA, 91: 7350-7354, 1994.
56. Shimizu, S., Eguchi, Y., Kosaka, H., Kamiike, W., Matsuda, H., and Tsujimoto, Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature (Lond.), 374: 811-813, 1995.
57. Cheng, E. H-Y., Levine, B., Boise, L. H., Thompson, C. B., and Hardwick, J. M. Bax-independent inhibition of apoptosis by Bcl-xL. Nature (Lond.), 379: 554-556, 1996.
58. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
59. Moulder, J. E., and Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5: 313-341, 1987.
60. Teicher, B. A., Lazo, J. S., and Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41: 73-81, 1981.
61. Stackpole, C. W., Groszek, L., and Kalbag, S. S. Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J. Natl. Cancer Inst., 86: 361-367, 1994.
62. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch. C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.